Home » Dana Goldman

About Dana Goldman

Dana Goldman is a Professor and the Leonard D. Schaeffer Director’s Chair at the University of Southern California. Until Fall 2009, he held RAND’s Distinguished Chair in Health Economics and directed RAND’s program in Economics, Finance, and Organization. He is also an Adjunct Professor of Health Services and Radiology at UCLA. More information about Dana can be found here.

Articles

Follow The Money: The Flow Of Funds In The Pharmaceutical Distribution System

Any government intervention to control drug pricing should be predicated on a clear understanding of the economic forces that drive price increases, and the parties responsible for them. (more…)

Why Academics Consulting with Industry on Health Care May be an Idea Whose Time has Come

At a time of deep political division, an academic approach to policy making has never been more important. (more…)

Election verdict: Pharma Needs a New Prescription

Dana Goldman and Darius Lakdawalla provide a policy prescription list for the pharmaceutical industry aimed at improving access for patients today without discouraging investments into tomorrow’s medical innovations.  (more…)

Hooked in Hospitals: Many Medicare Patients Received First Painkillers There

Understanding the context of opioid providing, provider patterns, and patient behavior is the first step to developing policies that will adequately halt this pressing public health crisis. Two studies co-written by Schaeffer Center researchers analyze this context within the Medicare population. (more…)

Predicting the Economic Impact of Changes to Population Health

So much of health care policy is decided by the science of the educated guess, with “what-if” forecasts at the heart of any analysis. (more…)

The Baby Boomers Will Shift the Health Status of the Medicare Population

A Typical Medicare Recipient in 2030

A new study by Schaeffer Center researchers Etienne Gaudette, Bryan Tysinger, and Dana Goldman predicts significant changes in the average future Medicare recipient. (more…)

For Vulnerable Populations, the Medicare Part D Doughnut Hole Disrupts Medication Adherence

During the annual Medicare Open Enrollment period, senior citizens (more…)

Medicare’s Big Fat Problem, Fiscal and Otherwise

Co-Authors: Dana Goldman, Bryan Tysinger, and Alwyn Cassil

You can’t draw a straight line between growing Medicare spending and expanding American waistlines. But policymakers would be wise to keep both in mind as they ponder how to pay for the health care of 75-million-plus baby boomers who likely will live longer in worse health thanks to rising rates of chronic conditions, (more…)

The US Hospital System May Be Outperforming Expectations

In a new Health Affairs article released in February, Schaeffer Center researchers provide evidence that hospital productivity increased from 2002 to 2011, suggesting that the US health care system could be performing better than many believe.  John Romley, Research Assistant Professor at the USC Schaeffer Center for Health (more…)

Benefits of Robotic-Assisted Surgery for Kidney Cancer Far Outweigh Investment Costs

The benefits of robotically-assisted surgery for patients with kidney cancer outweigh the healthcare and surgical costs by a ratio of five to one. This is according to new research published in Health Affairs(more…)

Why Bernie Sanders’s Plan for Universal Health Care is Only Half Right

Every American should automatically get health insurance, but Medicare for all isn’t the correct path towards that goal.  (more…)

Is investing in research to delay aging of value today?

The time is ripe for a new frontier in medicine. (more…)

Value-based drug pricing makes sense, but is difficult to pull off

Dana Goldman and Anupam Jena discuss the challenges of value-based pricing and health technology assessments. (more…)

Sky-High Drug Prices for Rare Diseases Show Why Orphan Drug Act Needs Reform

The Orphan Drug Act (ODA) was passed 34 years ago to promote development of drugs aimed at diseases that afflict small groups, typically under 200,000 people. However, the nature of drug development has changed. Our researchers see an opportunity for improvement. (more…)

To Prevent Another EpiPen Controversy, the Government Should Step In

The real problem is with lax regulatory oversight that doesn’t ensure an adequate supply of drugs critical to population health and opens the door to shocking price increases.  (more…)

What the Candidates Don’t Get About Drug Prices

If you are like me, you are watching with relish the presidential debates on both the Republican and Democratic side. Sometimes, amid the reality show-type theatrics, they actually substantive discussions about issues like Social Security, (more…)

Biomedical Research in the Age of Preventive Medicine

“Moonshot” was the word Google CEO Larry Page used to describe his newest venture, Calico–a biotech startup focused on the challenge of aging and age-associated pathology. In fact, medical therapies to delay aging are increasingly feasible, and, as shown by our study in Health Affairs, could achieve a far greater return on investment than comparable advances in the treatment of specific diseases. (more…)

Where Obamacare Went Wrong (Or Did It?)

By now, everyone has formed opinions of the Affordable Care Act (ACA). Ironically, the strongest opinions seem to come from people that know the least about it. (more…)

Don’t Be Fooled by Claims About the ACA Impact on Insurance Premiums

A recent New York Times headline reported that health plan costs for New Yorkers will fall 50%. They were taking the bait from Governor Cuomo’s office, who crowed about “real competition that helps drive down health insurance costs.” (more…)

Follow CESR on Facebook



Follow Schaeffer on Facebook